Introduction {#Sec1}
============

Pompe disease (Glycogen Storage Disease type II, acid maltase deficiency) is an autosomal recessive disorder caused by deficiency of the enzyme acid α-glucosidase. As a result of this deficiency, lysosomal glycogen cannot be degraded and accumulates in the lysosomes of virtually all body tissues \[[@CR7], [@CR16]\]. This leads to a broad clinical spectrum ranging from a severe, classic infantile phenotype with generalized muscle weakness, a hypertrophic cardiomyopathy and death usually before the first year of life \[[@CR28]\] to a slowly progressive proximal myopathy without involvement of the heart. Patients on this end of the spectrum are described as having 'late-onset' \[[@CR12], [@CR21]\] or 'nonclassic' \[[@CR31]\] Pompe disease and may present at any age, sometimes as late as the sixth decade of life. Eventually they may become wheelchair-bound and dependent on artificial ventilation \[[@CR7], [@CR16]\].

Besides symptoms related to weakness of the skeletal and respiratory muscles, non-motor problems such as fatigue can also have a profound and disabling impact on the patients' lives. Fatigue is difficult to define, as it is often a non-specific and subjective complaint. Two suggested definitions are 'extreme and persistent tiredness, weakness or exhaustion-mental, physical or both' \[[@CR6]\] and 'difficulty in initiation of or sustaining voluntary activities' \[[@CR3]\]. Although fatigue is a frequent symptom in many chronic disorders, it has received little attention in Pompe disease and was only sporadically reported \[[@CR4], [@CR20], [@CR23], [@CR27], [@CR32]\]. In a recent study on the clinical condition of late-onset Pompe patients we found that 76% of the study population reported symptoms of fatigue and that fatigue was among the first complaints for 24% \[[@CR12]\]. In the present study, we investigated the prevalence and severity of fatigue in more detail in a large, international group of adult patients with Pompe disease and studied the associations between fatigue and several other patient characteristics.

Methods {#Sec2}
=======

Patients and procedures {#Sec3}
-----------------------

Data were obtained between May 2002 and January 2004 as part of an ongoing international study on the natural course of Pompe disease in children and adults \[[@CR11]--[@CR13]\]. The medical ethical committee of Erasmus MC approved the project and the participants provided informed consent. Patients were recruited through patient organisations affiliated with the International Pompe Association (IPA). Participants were asked to complete a booklet of questionnaires, including one on fatigue for the patients of 18 years and older. The levels of fatigue in our study population were compared to those of healthy controls that were described previously in a study on immune-mediated polyneuropathies. This comparison group consisted of 113 healthy persons, 48% female, with a mean age of 54 (SD 15) years \[[@CR22]\].

Fatigue assessment {#Sec4}
------------------

The severity and impact of fatigue was assessed using the Fatigue Severity Scale (FSS) \[[@CR19]\]. The total FSS score is the average of the 9 item scores and ranges from 1 ('no signs of fatigue') to 7 ('most disabling fatigue'). Scores of 4 and higher indicate that patients are suffering from fatigue and scores of 5 and higher that patients are suffering from severe fatigue \[[@CR9], [@CR15], [@CR22]\]. We used the validated English and Dutch translations of the FSS \[[@CR19], [@CR22]\], and a German version that was translated by a certified translator. The FSS has demonstrated good internal consistency, reliability and validity in studies among patients with multiple sclerosis, immune-mediated polyneuropathies and chronic hepatitis C \[[@CR18], [@CR19], [@CR22]\] and is easy to complete. In the present study, individual item scores were missing for only 4% of the study population; the maximum number of missing items per patient was 3. When individual item scores were missing, the FSS score was calculated with the remaining items.

Other information {#Sec5}
-----------------

Additional information was gathered on date of birth, year of diagnosis, sex, use of wheelchair or walking aids, use of respiratory support, number of hours respiratory support per day, and presence of sleep disorders as indicated by the patient ('never', 'occasionally', or 'often'). Disease duration was calculated as the time between diagnosis and questionnaire completion.

Statistical analyses {#Sec6}
--------------------

Differences between countries in age, age at diagnosis, disease duration and FSS score (UK, USA, The Netherlands and Germany) were tested using one-way analysis of variance (ANOVA) and in sex, wheelchair use and use of respiratory support by χ^2^ tests. Mean scores of our study population were compared to the scores of healthy controls by calculating the t ratio using the published mean and standard deviation \[[@CR14], [@CR22]\]. Internal consistency was evaluated with Cronbach's alpha coefficient and test-retest reliability with the intraclass correlation coefficient \[[@CR24]\]. The test-retest reliability was determined in a subgroup of 34 Dutch patients who completed the FSS twice, with approximately 1 month between both measurements. The relation between FSS score and age, disease duration and number of hours ventilation per day was evaluated with Spearman's rank correlation coefficient.

Differences in mean FSS score between groups based on wheelchair and ventilator use and on the self-reported frequency of sleep disorders were tested with ANOVA. All analyses were performed using SPSS for Windows (version 11.5). A p-value of ≤0.05 was considered statistically significant.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

A total of 225 patients of 18 years and older completed the FSS. The mean age of the study population was 47 (SD 13) years and 54% were women. The mean disease duration was 11 (SD 8) years. Forty-three percent used a wheelchair and 46% used respiratory support, 29% needed both. The study population included patients from the USA (n = 75), the Netherlands (n = 50), Germany (n = 50), the UK (n = 17), Australia (n = 13), Canada (n = 8), Austria (n = 3), Switzerland (n = 2), Belgium, Denmark, Italy, Luxembourg, Spain, New Zealand and Taiwan (all n = 1). No statistically significant differences in patient characteristics between the countries were found.

FSS scores {#Sec9}
----------

The mean FSS score of the study population was 5.2 (SD 1.5). 78% of the patients had a FSS score of 4 or higher ('fatigued') and 67% a FSS score of 5 or higher ('severely fatigued'). The distributions of item scores are presented in Table [1](#Tab1){ref-type="table"}. Items on which 75% or more of the patients scored 5 or higher were mainly related to physical functioning: 'my fatigue prevents sustained physical functioning', 'fatigue interferes with my physical functioning' and 'exercise brings on my fatigue'. 65% of the patients classified fatigue among their three most disabling symptoms. Table 1Means and distribution of Fatigue Severity Scale item scores of 225 adult patients with Pompe diseaseScore distribution (%)ItemMean1--345--7My motivation is lower when I am fatigued5.79388Exercise brings on my fatigue5.710684Fatigue interferes with my physical functioning5.514581My fatigue prevents sustained physical functioning5.418676I am easily fatigued5.316975Fatigue interferes with carrying out certain duties and responsibilities5.023770Fatigue interferes with my work, family, or social life4.924967Fatigue is among my three most disabling symptoms4.829665Fatigue causes frequent problems for me4.8261163

The mean FSS score of our study population was significantly higher than the score of healthy controls (mean FSS score 2.9, p \< 0.001). Although the mean FSS score of the German Pompe patients was lower than the scores of patients from the UK, USA and the Netherlands (Fig. [1](#Fig1){ref-type="fig"}), it was still significantly higher than that of the Dutch healthy controls (p \< 0.001). The FSS showed excellent internal consistency in our international study population (Cronbach's alpha = 0.92 for the Dutch version and 0.94 for the English and German versions) and good 1-month test-retest reliability in the Dutch subgroup (intraclass correlation coefficient = 0.86). Fig. 1Mean scores (95% CI) on the Fatigue Severity Scale of adult patients with Pompe disease from different countries. FSS scores differed significantly between countries when tested with ANOVA (*p* \< 0.001). Scores of healthy controls were obtained from the literature \[[@CR22]\]

Relationship between fatigue and patient characteristics {#Sec10}
--------------------------------------------------------

FSS scores were not related to sex (p = 0.26), age or disease duration (r = )0.05 and )0.03, p \> 0.47). Figure [2](#Fig2){ref-type="fig"} shows the FSS score in groups based on wheelchair and ventilator use. When tested in four groups, no significant differences in FSS score were found, but patients who did not use a wheelchair or respiratory support were less fatigued than those who used one or both of these aids (FSS score = 4.9 vs. 5.4, p = 0.01). However, even in the group of patients who did not use a wheelchair or respiratory support, 71% had a FSS score ≥4 and 59% had a FSS score ≥5. Within the group of patients who used respiratory support, FSS scores were not correlated to the number of hours of ventilation per day (r = 0.06, p = 0.57). Although the FSS scores differed significantly between patients reporting 'never', 'occasionally' and 'often' sleep disorders, the scores were high in all three groups (mean FSS score 4.8, 5.3 and 5.6, respectively; p = 0.01). Fig. 2Mean scores (95% CI) on the Fatigue Severity Scale of adult patients with Pompe disease related to wheelchair use and use of respiratory support

Discussion {#Sec11}
==========

This study shows that fatigue is prevalent in the entire spectrum of mildly and severely affected adult patients with Pompe disease. The FSS scores in this international group of Pompe patients were significantly higher than the scores of healthy controls. Although we found a significant difference in FSS score between patients with and those without wheelchair or respiratory support, even in the least affected group more than half of the patients had FSS scores ≥5, indicating severe fatigue. FSS scores were not correlated with the duration of disease. The high level of fatigue in our study population, as measured with the FSS, is comparable to that of other chronic disorders such as postpoliomyelitis syndrome (mean score 5.7, mean age 52, SD 8, n = 65) \[[@CR17]\] and multiple sclerosis (mean score 5.3, mean age 45, SD 10, n = 25) \[[@CR19]\].

Although all mean FSS scores were high, significant differences existed between patients from different countries. The lowest scores were obtained in the German population. This could not be explained by differences in general characteristics. It is conceivable that the impact of fatigue differs somewhat across countries, since social attitudes, expectations and roles may differ as well \[[@CR2]\]. It should also be noted that the German translation of the FSS had not been used before and needs further (cross-cultural) validation. Yet, excellent internal consistency in all languages, as well as good reliability, suggests that the FSS can be a useful tool for assessing fatigue in Pompe disease.

For an optimal treatment of fatigue it is important to know why it is so prominently present in Pompe disease. In a recent review the contribution of 'central' and 'peripheral' components to fatigue in neurological disorders has been discussed \[[@CR3]\]. In Pompe disease, a peripheral cause of fatigue, resulting from muscle weakness, is perhaps the most likely explanation. Especially relevant with respect to fatigue in Pompe disease is weakness of the respiratory muscles. Respiratory insufficiency may lead to fragmented sleep, which in turn may lead to daytime sleepiness and fatigue \[[@CR21]\]. In the present study, patients who reported 'often' or 'occasionally' sleep disorders were on average more fatigued, but patients who reported to have 'never' sleep difficulties also had high FSS scores. It is possible that fragmented sleep due to respiratory insufficiency has remained unnoted in some of the patients in the latter group, and we and others previously advised that respiratory function should be monitored in all patients with Pompe disease, irrespective of their motor function \[[@CR12], [@CR25], [@CR29]\].

Another possible explanation is the relationship between fatigue and depression \[[@CR1], [@CR5], [@CR8]\]. We did not investigate the presence of depression specifically, but found earlier that patients with Pompe disease score equal to the general population on the mental health scale of the SF-36, a health-related quality of life questionnaire \[[@CR11]\]. Nevertheless it is recommended to study the possible influence of depression in more detail in future studies, for example by means of the Hospital Anxiety and Depression Scale \[[@CR33]\].

Thus, although a peripheral cause of fatigue is probably the most important factor, the underlying mechanisms of fatigue in Pompe disease are in fact not known yet and a possible central contribution should not a priori be excluded in future studies. Noteworthy, in a study with enzyme replacement therapy (ERT) in three patients with moderate to severe late-onset Pompe disease, less fatigue and increased energy was one of the first improvements reported by the patients \[[@CR30]\]. This was independent of disease severity and motor response to treatment. It would therefore be interesting to include a standardized measure of fatigue in future clinical trials on the effect of ERT. In multiple sclerosis, Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy adherence to an aerobic training programme resulted in a significant decrease in fatigue and an improvement in physical fitness and quality of life \[[@CR10], [@CR26]\]. Part of the training effect is probably due to increased fitness of the participants and social aspects of the intervention \[[@CR26]\], and in this respect it is worthwhile to study the effects of a medically supervised low-intensity training programme on fatigue and general well-being of patients with Pompe disease.

In conclusion, our findings indicate that fatigue is highly prevalent among adult patients with Pompe disease. It is present in both mildly and severely affected patients and is independent of disease duration. The FSS appears a useful tool for the assessment of fatigue in adult patients with Pompe disease. Further research is needed to unravel the pathophysiological mechanism and to identify targets for fatigue management.
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